- Evaluate major bleeding and stroke or systemic embolism in NVAF patients in real world clinical settings, ranging from primary care practices to cardiologists’ offices and hospitals1
- A large, prospective, observational, single-arm, non-interventional study to evaluate the safety and efficacy of Xarelto® in the real world1
- Patients were enrolled from June 2012 to December 2013 from 311 centres in Europe, Canada and Israel1
- 6,784 adults with NVAF newly receiving once-daily Xarelto for prevention of stroke and systemic embolism for NVAF were followed for 1 year, or 30 days following permanent treatment discontinuation1
NVAF, non-valvular atrial fibrillation. AF , atrial fibrillation. CHF, congestive heart failure. TIA , transient ischaemic attack. LVEF , left ventricular ejection fraction. CrCl, creatinine clearance. CHADS2-score is used to estimate stroke risk in patients with NVAF. aOr LVEF <40%. bFor Xantus patients, figure related to only age >75 years old. cFor Xantus patients, this also could have included prior systemic embolism. dModerate renal impairment was defined as CrCl 30–49 ml/min in ROCKET AF. e34.4% of patients had unknown CrCl values. fModerate to severe renal impairment was defined as CrCl <50 ml/min in Xantus. gXarelto is only approved for stroke prevention in NVAF patients with one or more risk factors.
- XARELTO is evidenced across the full CHADS2-scores risk spectrum.1,2
XANTUS real world evidence reflects the patients seen frequently in general practice.